The role of IL-17 rs2275913, IL-17RC rs708567 and TGFB1 rs1800469 SNPs and IL-17A serum levels in patients with lupus nephritis.


Journal

Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 18 06 2021
accepted: 13 09 2021
pubmed: 24 9 2021
medline: 21 1 2022
entrez: 23 9 2021
Statut: ppublish

Résumé

Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease and polymorphisms in the cytokine genes and their receptors are thought to influence its development. The aim of this case-control study was to investigate the association of the IL-17A rs2275913, IL-17RC rs708567 and TGFB1 rs1800469 polymorphisms with SLE, its clinical manifestations and the polymorphisms influence on the IL-17A serum levels. Altogether 59 SLE patients with lupus nephritis and 95 healthy controls were genotyped by TaqMan assay. Serum levels were determined by Human IL-17A Platinum ELISA kit. From the studied polymorphisms, only TGFB1 T allele was found to be associated with SLE. Within the patient group, IL-17A GG genotype and TGFB1 -509T allele showed an association with the neurological disease and IL-17RC CC genotype appeared to be associated with lupus arthritis. The IL17A serum levels in the SLE and control groups (7.24 pg/ml and 5.76 pg/ml, respectively) did not show any statistical difference. A weak correlation between IL17A levels and SLEDAI-2K was observed. Our results indicate that IL-17A rs2275913, IL-17RCrs708567 and TGFB1 rs1800469 polymorphisms might play a role in the susceptibility and the clinical manifestations of SLE and IL-17A serum levels should be monitored in the course of the disease. The identification of subsets of SLE with an IL-17-driven disease could improve the therapeutic approach leading to more precise personalized treatment.

Identifiants

pubmed: 34554306
doi: 10.1007/s00296-021-04996-z
pii: 10.1007/s00296-021-04996-z
doi:

Substances chimiques

IL17A protein, human 0
Interleukin-17 0
Receptors, Interleukin-17 0
TGFB1 protein, human 0
Transforming Growth Factor beta1 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2205-2213

Subventions

Organisme : Medical University-Sofia
ID : D-67/2016

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

de Morales J, Puig L, Dauden E et al (2020) Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies. Autoimm rev 19(1):102429. https://doi.org/10.1016/j.autrev.2019.102429
doi: 10.1016/j.autrev.2019.102429
Koga T, Ichinose K, Kawakami A, Tsokos GC (2019) The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutictarget. Expert Rev Clin Immunol 15(6):629–637. https://doi.org/10.1080/1744666X.2019.1593141
doi: 10.1080/1744666X.2019.1593141 pubmed: 30874446
Hatton RD (2011) TGF-β in Th17 cell development: the truth is out there. Immunity 34(3):288–290. https://doi.org/10.1016/j.immuni.2011.03.009
doi: 10.1016/j.immuni.2011.03.009 pubmed: 21435582 pmcid: 3097895
Manolova I, Gerenova J, Ivanova M (2013) Serum levels of transforming growth factor-β1 (TGF-β1) in patients with systemic lupus erythematosus and Hashimoto’s thyroiditis. Eur Cytokine Netw 24(1):69–74. https://doi.org/10.1684/ecn.2013.0331
doi: 10.1684/ecn.2013.0331 pubmed: 23614931
Antiga E, Del Bianco E, Difonzo E, Fabbri P, Caproni M (2011) Serum levels of the regulatory cytokines transforming growth factor-β and interleukin-10 are reduced in patients with discoid lupus erythematosus. Lupus 20(6):556–560. https://doi.org/10.1177/0961203310392424
doi: 10.1177/0961203310392424 pubmed: 21372199
Peng Z, Zhan L, Chen S, Xu E (2011) Association of transforming growth factor-β1 gene C-509T and T869C polymorphisms with atherosclerotic cerebral infarction in the Chinese: a case-control study. Lipids Health Dis 10:100. https://doi.org/10.1186/1476-511X-10-100
doi: 10.1186/1476-511X-10-100 pubmed: 21679448 pmcid: 3129580
Grainger DJ, Heathcote K, Chiano M et al (1999) Genetic control of the circulating concentration of transforming growth factor type β1. Hum Mol Genet 8(1):93–97. https://doi.org/10.1093/hmg/8.1.93
doi: 10.1093/hmg/8.1.93 pubmed: 9887336
Crispin JC, Oukka M, Bayliss G et al (2008) Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 181(12):8761–8766. https://doi.org/10.4049/jimmunol.181.12.8761
doi: 10.4049/jimmunol.181.12.8761 pubmed: 19050297
Yang J, Chu Y, Yang X et al (2009) Th17 and natural treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 60(5):1472–1483. https://doi.org/10.1002/art.24499
doi: 10.1002/art.24499 pubmed: 19404966
Wong CK, Lit LCW, Tam LS et al (2008) Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 127(3):385–393. https://doi.org/10.1016/j.clim.2008.01.019
doi: 10.1016/j.clim.2008.01.019 pubmed: 18373953
Xing Q, Wang B, Su H et al (2012) Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatol Int 32(4):949–958. https://doi.org/10.1007/s00296-010-1771-0
doi: 10.1007/s00296-010-1771-0 pubmed: 21243492
Wong CK, Ho CY, Li EK, Lam CWK (2000) Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 9(8):589–593. https://doi.org/10.1191/096120300678828703
doi: 10.1191/096120300678828703 pubmed: 11035433
Doreau A, Belot A, Bastid J et al (2009) Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 10(7):778–785. https://doi.org/10.1038/ni.1741
doi: 10.1038/ni.1741 pubmed: 19483719
Hammad A, Osman E, Mosaad Y, Wahba M (2017) Serum interleukin-17 in Egyptian children with systemic lupus erythematosus: is it related to pulmonary affection? Lupus 26(4):388–395. https://doi.org/10.1177/0961203316665709
doi: 10.1177/0961203316665709 pubmed: 27587461
Gunawan A, Susianti H, Indyanty E et al (2016) The association between G-197A gene polymorphism of IL-17A with changes in protein interaction of IL-17A, levels of urinary IL-17, and degree of lupus nephritis abnormality. Comp Clin Pathol 25:535–541. https://doi.org/10.1007/s00580-016-2222-4
doi: 10.1007/s00580-016-2222-4
Shu Q, Yang P, Hou S et al (2010) Interleukin-17 gene polymorphism is associated with Vogt-Koyanagi-Harada syndrome but not with Behçet’s disease in a Chinese Han population. Hum Immunol 71(10):988–991. https://doi.org/10.1016/j.humimm.2010.06.020
doi: 10.1016/j.humimm.2010.06.020 pubmed: 20620187
Holster A, Teräsjärvi J, Lauhkonen E et al (2018) IL-17A gene polymorphism rs2275913 is associated with the development of asthma after bronchiolitis in infancy. Allergol Int 67(1):109–113. https://doi.org/10.1016/j.alit.2017.05.010
doi: 10.1016/j.alit.2017.05.010 pubmed: 28647382
Xu H, Pan Y, Li W et al (2016) Association between IL17A and IL17F polymorphisms and risk of Henoch-Schonlein purpura in Chinese children. Rheumatol Int 36(6):829–835. https://doi.org/10.1007/s00296-016-3465-8
doi: 10.1007/s00296-016-3465-8 pubmed: 27021337
Ho AW, Gaffen SL (2010) IL-17RC: a partner in IL-17 signaling and beyond. Semin Immunopathol 32(1):33–42. https://doi.org/10.1007/s00281-009-0185-0
doi: 10.1007/s00281-009-0185-0 pubmed: 20012905
Zhou S, Qiu XS, Zhu ZZ, Wu WF, Liu Z, Qiu Y (2012) A single-nucleotide polymorphism rs708567 in the IL-17RC gene is associated with a susceptibility to and the curve severity of adolescent idiopathic scoliosis in a Chinese Han population: a case-control study. BMC Musculoskelet Disord 13:181. https://doi.org/10.1186/1471-2474-13-181
doi: 10.1186/1471-2474-13-181 pubmed: 22999050 pmcid: 3517504
Petri M, Orbai AM, Alarcón GS et al (2012) Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686. https://doi.org/10.1002/art.34473
doi: 10.1002/art.34473 pubmed: 22553077 pmcid: 3409311
Zhao XF, Pan HF, Yuan H et al (2010) Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 37(1):81–85. https://doi.org/10.1007/s11033-009-9533-3
doi: 10.1007/s11033-009-9533-3 pubmed: 19347604
Shen HH, Fan YN, Zhao CN et al (2020) Elevated circulating Interleukin-17 levels in patients with systemic lupus erythematosus: a meta-analysis. Immunol Invest 49(6):662–675. https://doi.org/10.1080/08820139.2019.1699107
doi: 10.1080/08820139.2019.1699107 pubmed: 31847623
Vincent FB, Northcott M, Hoi A et al (2013) Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res Ther 15(4):R97. https://doi.org/10.1186/ar4277
doi: 10.1186/ar4277 pubmed: 23968496 pmcid: 3979031
PeliçariKde O, Postal M, Sinicato NA et al (2015) Serum interleukin-17 levels are associated with nephritis in childhood-onset systemic lupus erythematosus. Clinics (Sao Paulo) 70(5):313–317. https://doi.org/10.6061/clinics/2015(05)01
doi: 10.6061/clinics/2015(05)01
Xie M, Cheng B, Ding Y et al (2019) Correlations of IL-17 and NF-κB gene polymorphisms with susceptibility and prognosis in Acute Respiratory Distress Syndrome in a Chinese population. Biosci Rep. https://doi.org/10.1041/BSR20181987
Espinoza JL, Takami A, Nakata K et al (2011) A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PLoS ONE 6(10):e26229. https://doi.org/10.1371/journal.pone.0026229
doi: 10.1371/journal.pone.0026229 pubmed: 22028838 pmcid: 3197629
Dhaouadi T, Chahbi M, Haouami Y et al (2018) IL-17A, IL-17RC polymorphisms and IL17 plasma levels in Tunisian patients with rheumatoid arthritis. PLoS ONE 13(3):e0194883. https://doi.org/10.1371/journal.pone.0194883
doi: 10.1371/journal.pone.0194883 pubmed: 29584788 pmcid: 5870983
Montúfar-Robles I, Barbosa-Cobos R, Alemán-Ávila I, Ramírez-Bello J (2019) IL17A haplotype confers susceptibility to systemic lupus erythematosus but not to rheumatoid arthritis in Mexican patients. Int J Rheum Dis 22(3):473–479. https://doi.org/10.1111/1756-185X.13426
doi: 10.1111/1756-185X.13426 pubmed: 30398030
Sharifzadeh M, Naeimi S, Nasiri M et al (2018) IL-17A gene polymorphism at position G197A and systemic lupus erythematosus. Rheumatol Res 3(3):107–112
doi: 10.22631/rr.2018.69997.1050
Paradowska-Gorycka A, Roszak M, Stypinska B et al (2019) IL-6 and TGF-β gene polymorphisms, their serum levels, as well as HLA profile, in patients with systemic lupus erythematosus. Clin Exp Rheumatol 37(6):963–975
pubmed: 30943147
Georgiev T, Stoilov R (2019) Bulgarian Rheumatology: science and practice in a cost-constrained environment. Rheumatol Int 39(3):417–429. https://doi.org/10.1007/s00296-018-4202-2
doi: 10.1007/s00296-018-4202-2 pubmed: 30413925

Auteurs

Maria Hristova (M)

Clinic of Nephrology, Department of Internal Medicine, University Hospital St Ivan Rilski, Medical University-Sofia, Sofia, Bulgaria. bulgaria_neo@yahoo.co.uk.

Zornitsa Kamenarska (Z)

Molecular Medicine Center, Medical University-Sofia, 2 Zdrave Street, 1431, Sofia, Bulgaria.

Gyulnas Dzhebir (G)

Molecular Medicine Center, Medical University-Sofia, 2 Zdrave Street, 1431, Sofia, Bulgaria.

Svetla Nikolova (S)

Molecular Medicine Center, Medical University-Sofia, 2 Zdrave Street, 1431, Sofia, Bulgaria.

Rozalia Hristova (R)

Department of Ophthalmology, Medical University-Sofia, Alexandrovska Hospital, 1 GeorgiSofijski Street, 1431, Sofia, Bulgaria.

Kalina Mihova (K)

Molecular Medicine Center, Medical University-Sofia, 2 Zdrave Street, 1431, Sofia, Bulgaria.

Anton Vinkov (A)

Hôpitaux Drôme Nord, 607 avenue Geneviève de Gaulle-Anthonioz, 26102, Romans-sur-Isère, France.

Tsvetoslav Georgiev (T)

Clinic of Rheumatology, First Department of Internal Medicine, University Hospital "St Marina", Medical University-Varna, 9002, Varna, Bulgaria.

Joana Pozharashka (J)

Department of Dermatology and Venereology, Medical University-Sofia, 1 Georgi Sofijski Street, 1431, Sofia, Bulgaria.

Radka Kaneva (R)

Molecular Medicine Center, Medical University-Sofia, 2 Zdrave Street, 1431, Sofia, Bulgaria.
Department of Medical Chemistry and Biochemistry, Medical University -Sofia, 2 Zdrave Street, 1431, Sofia, Bulgaria.

Alexey Savov (A)

National Genetic Laboratory, Medical University Sofia, 2 Zdrave Street, 1431, Sofia, Bulgaria.

Atanas Koundurdjiev (A)

Clinic of Nephrology, Department of Internal Medicine, University Hospital St Ivan Rilski, Medical University-Sofia, Sofia, Bulgaria.

Lyubomir Dourmishev (L)

Department of Dermatology and Venereology, Medical University-Sofia, 1 Georgi Sofijski Street, 1431, Sofia, Bulgaria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH